SCHEMBL29847788

SCHEMBL29847788

CN(C)CCOc1cccc(-c2nccc3cnc(Nc4ccc(N5CCOCC5)cc4)nc23)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 1/20 0.46
▸ CDK2 P24941 4/20 0.46
▸ CDK1 P06493 3/20 0.46
▸ CDK4 P11802 3/20 0.46
▸ CCNB1 P14635 3/20 0.46
▸ CCND1 P24385 3/20 0.46
▸ CCNE1 P24864 3/20 0.46
▸ JAK2 O60674 5/20 0.46
▸ FGFR4 P22455 2/20 0.46
▸ PLK4 O00444 1/20 0.46
▸ TTK P33981 2/20 0.44
▸ JUN P05412 1/20 0.44
▸ MAPK8 P45983 1/20 0.44
▸ MAPK10 P53779 1/20 0.44
▸ PTK2 Q05397 2/20 0.44
▸ CCNA2 P20248 1/20 0.44
▸ FGFR1 P11362 1/20 0.43
▸ KDR P35968 1/20 0.43
▸ EPHB4 P54760 1/20 0.43
▸ ACVR1 Q04771 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16515322 1.00 SYK (0.46) SYKCDK2CDK1CDK4CCNB1
SCHEMBL16515089 0.91 BRAF (0.44) SYKCDK2TTKCCNA2FGFR1
SCHEMBL29847932 0.91 BRAF (0.44) SYKCDK2TTKCCNA2FGFR1
SCHEMBL16823266 0.91 CDK2 (0.47) CDK2CDK1CDK4CCNB1CCND1
SCHEMBL31679049 0.91 CDK2 (0.47) CDK2CDK1CDK4CCNB1CCND1
SCHEMBL16515298 0.90 CDK2 (0.49) CDK2CDK1CDK4CCNB1CCND1
SCHEMBL29847518 0.90 CDK2 (0.49) CDK2CDK1CDK4CCNB1CCND1
SCHEMBL16514481 0.89 MAPK10 (0.55) SYKCDK2CDK1CDK4CCNB1
SCHEMBL29847732 0.89 SRC (0.47) SYKCDK2CDK1CDK4CCNB1
SCHEMBL16823173 0.89 SRC (0.47) SYKCDK2CDK1CDK4CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12403145-B2 Substituted quinazolines for inhibiting kinase activity NEUPHARMA, INC (US) 2025-09-02 — — US claimed
CN-109851617-B Chemical entities, compositions, and methods 润新生物公司 2022-08-16 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12403145-B2 Substituted quinazolines for inhibiting kinase activity DCK, ABL1, MAP4K2 SYK 721/4885CDK2 35/4885CDK1 100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback